

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope, with sufficient postage, addressed to: Commissioner for Patents, Washington, D.C. 20231, on

February 12, 2003

Date of Deposit

J. Matthew Buchanan, Reg. No. 47,459

Name of Applicant, Assignee or
Registered Representative


Signature

12 February 2003
Date of Signature

PH#16

RECEIVED
FEB 21 2003
TECH CENTER 1600/2900

Our Case No.: 10709/14

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Thomas J. Schall et al.

Serial No.: 10/001,221

Filing Date: October 30, 2001

For: METHODS AND COMPOSITIONS
FOR INDUCING AN IMMUNE
RESPONSE

Examiner: N/A

Group Art Unit No.: 1614

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this First Supplemental Information Disclosure Statement be entered and the documents listed below and on the attached Form PTO-1449 be considered by the

Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

The references now cited are the following:

DOCUMENT NO.	DATE	COUNTRY
WO 99 29728 A	17 June 1999	PCT
EP 0 974 357 A	26 January 2000	European Patent Office
WO 98 04282 A	2 February 1998	PCT
WO 01 80887 A	1 November 2001	PCT


OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)
De Giovanni, Carla et al., "The Prospects For Cancer Gene Therapy", <i>International Journal of Immunopharmacology</i> , vol. 22, no. 12, 2000, pp. 1025-1032
Greaves, David R. et al., "Chemokines and Myeloid Cell Recruitment", <i>Microbes and Infection</i> , vol. 2, no. 3, 2000, pp. 331-336

This First Supplemental Information Disclosure Statement is being filed prior to the receipt of the first Official Action reflecting an examination on the merits and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with filing of this First Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Brinks Hofer Gilson & Lione Deposit Account No. 23-1925. A duplicate copy of this document is enclosed.

In accordance with 37 C.F.R. § 1.97(e)(1), Applicant(s) hereby certify that each item of the information disclosed in this First Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to filing of the present statement, as evidenced by the date of the enclosed search report.

Applicant(s) respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



J. Matthew Buchanan
Registration No. 47,459
Attorney for Applicant(s)

BRINKS HOFER GILSON & LIONE
P.O. Box 10395
Chicago, IL 60610
(312) 321-4200

